Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-DOTATATE in 68Ga-DOTATATE Positive Neuroendocrine Tumors
NCT02743741Completed
- Sponsor
- University Health Network
- Start
- Jul 2016
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by University Health Network. Primary endpoint: Progression-Free Survival at 12 months. Started Jul 2016; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02743741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743741.